Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBarr (A.G.) Regulatory News (BAG)

Share Price Information for Barr (A.G.) (BAG)

Share Price is delayed by 15 minutes
Get Live Data
613.00    6.00 (0.99%)
Bid:
610.00
Ask:
612.00
Spread: 2.00 (0.328%)
Market Cap: £680.28m
BAG Live PriceLast checked at - London Stock Exchange

Intraday Barr (A.G.) Share Chart

Trading Statement

29 Jul 2025 07:00

RNS Number : 8564S
Barr(A.G.) PLC
29 July 2025
 

IMMEDIATE RELEASE 29 July 2025

A.G. BARR p.l.c

("A.G. BARR" or "the Company")

 

Trading Update

 

Continued revenue & profit growth; Full Year expectations unchanged

 

A.G. BARR p.l.c., the multi-beverage business with a portfolio of market-leading UK brands including IRN-BRU, Rubicon, Boost and FUNKIN, today announces a trading update for the 26 weeks ended 26 July 2025 (H1 2025/26).

H1 2025/26 Trading

H1 2025/26 revenue is expected to be c.£228m, c.3% up on the prior year (H1 2024/25: £221.3m). Overall, the Company's trading momentum increased as H1 progressed, with several record volume weeks in Q2.

Brand revenue performance was led by Boost which delivered strong double-digit growth. IRN-BRU and Rubicon were flat in H1, with a stronger performance in Q2. FUNKIN saw continued off-trade growth partly mitigating challenges in on-trade, with the overall trend improving during H1 and positive in Q2. 

H1 adjusted operating margin is anticipated to be ahead of last year at c.15.0% (H1 2024/25: 13.0%) driven by improved manufacturing efficiencies, on-going benefits from our strategic business improvement initiatives and continued disciplined cost management.

Strategy Update

We are pleased to announce the Company has acquired a 50.1% equity stake in Innate-Essence Ltd, for an initial consideration of £15 million. Innate-Essence is the home of The Turmeric Co., a leading brand in the functional shots market, as well as a number of other speciality health drinks.

This is consistent with the Company's strategy of acquisitions and innovation in high growth, health focused, functional beverage categories. The investment has been funded from the Company's net cash position. It is not expected to have a significant impact on revenue or profit in the current financial year.

The Company has also concluded the sale of the Strathmore brand and the Forfar production site to Tŷ Nant, negatively impacting revenue in the short-term but not profit.

Full Year Outlook

Our revenue and profit growth expectations for the full year are unchanged. We are confident that H2 will see a strong rate of year-on-year revenue growth. We have made excellent progress with operating margin during H1 and expect to deliver a full year result in line with expectations after taking into account a planned higher level of marketing activity in H2.

Euan Sutherland, Chief Executive Officer, commented:

"We are pleased to report continued revenue growth and strong profit growth in the first half of the financial year. Trading improved during H1 and we enter H2 with strong momentum and continued progress on margin improvement as our strategic initiatives continue to deliver. I am also excited about our expansion into the functional beverage segment working alongside Thomas Robson-Kanu and the Innate-Essence team. Our full year guidance remains unchanged and in line with market expectations."

For more information, please contact :

A.G. BARR  MHP GROUP

0330 390 3900 07801 894 577

Euan Sutherland, Chief Executive Officer agbarr@mhpgroup.com

Stuart Lorimer, Chief Finance and Operating Officer Oliver Hughes

Ewan Dytch, Corporate Finance Director Rachel Farrington

Veronica Farah

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTUWOSRVSUBUAR
Date   Source Headline
11th Jul 202210:32 amRNSDirector/PDMR Shareholding
16th Jun 202210:14 amRNSDirector/PDMR Shareholding
16th Jun 202210:04 amRNSDirector/PDMR Shareholding
15th Jun 202210:23 amRNSDirector/PDMR Shareholding
13th Jun 20221:42 pmRNSDirector/PDMR Shareholding
13th Jun 20221:40 pmRNSDirector/PDMR Shareholding
8th Jun 20229:53 amRNSDirectorship
27th May 20221:55 pmRNSResult of AGM
23rd May 20229:55 amRNSDirector/PDMR Shareholding
11th May 20228:53 amRNSDirector/PDMR Shareholding
26th Apr 20229:08 amRNSAnnual Financial Report / Notice of AGM
11th Apr 20221:11 pmRNSDirector/PDMR Shareholding
11th Apr 20228:51 amRNSDirector/PDMR Shareholding
11th Apr 20228:45 amRNSDirector/PDMR Shareholding
30th Mar 20227:00 amRNSDirectorate Change
29th Mar 20222:34 pmRNSDirector/PDMR Shareholding
29th Mar 20229:37 amRNSCorrection: Final results year ended 30 Jan 2022
29th Mar 20227:00 amRNSFinal results for the year ended 30 January 2022
18th Mar 20229:02 amRNSHolding(s) in Company
8th Mar 20222:14 pmRNSDirector/PDMR Shareholding
9th Feb 20227:56 amRNSDirector/PDMR Shareholding
4th Feb 20228:32 amRNSHolding(s) in Company
4th Feb 20228:27 amRNSHolding(s) in Company
1st Feb 20227:00 amRNSTrading Update
26th Jan 202210:35 amRNSNotice of Trading Update
11th Jan 202211:28 amRNSDirector/PDMR Shareholding
8th Dec 202112:59 pmRNSDirector/PDMR Shareholding
6th Dec 20217:00 amRNSInvestment in MOMA Foods Limited
29th Nov 20217:00 amRNSTrading Update
8th Nov 20212:15 pmRNSDirector/PDMR Shareholding
3rd Nov 20211:21 pmRNSDirector/PDMR Shareholding
3rd Nov 20219:37 amRNSDirector/PDMR Shareholding
1st Nov 202112:50 pmRNSDirector/PDMR Shareholding
11th Oct 20212:15 pmRNSDirector/PDMR Shareholding
11th Oct 20218:12 amRNSDirector/PDMR Shareholding
1st Oct 20218:49 amRNSDirector/PDMR Shareholding
1st Oct 20218:33 amRNSDirector/PDMR Shareholding
28th Sep 20217:00 amRNSInterim results
8th Sep 202111:39 amRNSDirector/PDMR Shareholding
31st Aug 202110:37 amRNSNotice of Interim Results Date
9th Aug 202111:21 amRNSDirector/PDMR Shareholding
3rd Aug 20217:00 amRNSH1 trading update to 1 August 2021
20th Jul 20217:00 amRNSTrading Update
19th Jul 20212:22 pmRNSHolding(s) in Company
9th Jul 20217:55 amRNSDirector/PDMR Shareholding
6th Jul 20213:32 pmRNSDirector/PDMR Shareholding - AMENDMENT
6th Jul 202112:11 pmRNSDirector/PDMR Shareholding
25th Jun 20217:00 amRNSDirectorate Changes
10th Jun 20219:01 amRNSHolding(s) in Company
8th Jun 20213:33 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.